Pacritinib
As of the edition of 20 October 2026, Pacritinib is a small molecule: marketed, first approved in 2022 (US); acts on FLT3 and JAK2; US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Vonjo
- First approved
- 28 February 2022 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Swedish Orphan Biovitrum
- Registered trials
- 54, 16 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Lungs and airways; Urinary and reproductive
US protection
US protection ends in 2030.
The last listed US drug-substance patent ends in 2030. The application that gives this date is held by Swedish Orphan Biovitrum.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product6 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 6 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Pacritinib.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 19 | 11 | 5 | 3 |
| Phase 2 | 32 | 5 | 16 | 11 |
| Phase 3 | 3 | 0 | 1 | 2 |
| All trials | 54 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Swedish Orphan Biovitrum | Originator, Applicant and Lead sponsor of trials | 2013 to now |